PA
AERI

Profund Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Profund Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-6,391
Closed -$231K – 1253
2018
Q4 		$231K Sell
6,391
-1,184
-16% -$55.5K 0.01% 947
2018
Q3 		$466K Buy
+7,575
New +$487K 0.02% 878

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Profund Advisors's AERI Position: Q1 2019 in Review

Profund Advisors sold out of Aerie Pharmaceuticals (AERI) in Q1 2019, closing a stake of 6,391 shares — an estimated $231K sold.

Profund Advisors first reported a position in AERI in Q3 2018 and held it in 2 quarters. The position peaked at $466K in Q3 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q1 2019.

  • Profund Advisors reported no remaining Aerie Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Profund Advisors sold 6,391 Aerie Pharmaceuticals shares in Q1 2019, an estimated $231K.
  • Profund Advisors first reported a position in Aerie Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Profund Advisors's Aerie Pharmaceuticals position peaked at $466K in Q3 2018.
  • 176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2019.

Based on Profund Advisors's 13F filing for Q1 2019, filed 15 May 2019.